Trifluridine–Tipiracil for Previously Treated Metastatic Colorectal Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

@inproceedings{Ramaekers2017TrifluridineTipiracilFP,
  title={Trifluridine–Tipiracil for Previously Treated Metastatic Colorectal Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal},
  author={Bram L T Ramaekers and Robert F. Wolff and Anoukh van Giessen and Xavier Ghislain L{\'e}on Victor Pouwels and Debra Fayter and Shona H Lang and Nigel T Armstrong and Gillian Worthy and Steven Duffy and Jos M P Kleijnen and Manuela M A Joore},
  booktitle={PharmacoEconomics},
  year={2017}
}
The National Institute for Health and Care Excellence (NICE) invited Servier, the company manufacturing trifluridine and tipiracil (T/T; trade name: Lonsurf®), to submit evidence for the clinical and cost effectiveness of T/T compared with best supportive care (BSC) for metastatic colorectal cancer (third-line or later). Kleijnen Systematic Reviews Ltd (KSR… CONTINUE READING